Ohio’s revised rule for controlled medications used to treat obesity took effect February 28, 2023. This announcement has been updated to clarify the ongoing requirements; read the current official rule alongside your provider’s instructions.
Continuation requires more than reaching three months
The rule permits continued treatment when its conditions are met. Patients must achieve at least 5% loss of initial weight in the first three months. Continuing a medication labeled for short-term use beyond three months requires maintaining that reduction, documented benefit and tolerability, and follow-up at least every three months, including weight, blood pressure, and heart rate. The rule contains additional eligibility and monitoring requirements.
Phentermine’s FDA labeling remains for short-term use; longer treatment is off-label. Your provider must assess whether continuation is appropriate. See the Adipex-P prescribing information.
For JourneyLite’s visit schedule, interruption-of-treatment questions, and the distinction between state rules and medication labeling, read our prescribing and follow-up guide. Your care team will confirm whether a visit can be virtual.
Planning a visit? Explore JourneyLite’s medical weight loss program and review medication costs and coverage before requesting a consultation.
Appointment Request-Simple (Main)
"*" indicates required fields
